BRAF mutation

News alerts, weekly reports and conference planners

Entrez ID:

673

Related biomarkers:

‹

›

BRAF mutation	Melanoma	BRAF mutation	Melanoma	dabrafenib + granisetron intravenous Sensitive: A2 - Guideline dabrafenib + granisetron intravenous Sensitive : A2	dabrafenib + granisetron intravenous Sensitive: A2 - Guideline dabrafenib + granisetron intravenous Sensitive : A2
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	ziv-aflibercept IV Sensitive: B - Late Trials ziv-aflibercept IV Sensitive : B	ziv-aflibercept IV Sensitive: B - Late Trials ziv-aflibercept IV Sensitive : B
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	cetuximab Resistant: B - Late Trials cetuximab Resistant : B	cetuximab Resistant: B - Late Trials cetuximab Resistant : B
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
BRAF mutation	Melanoma	BRAF mutation	Melanoma	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	FOLFIRI + cetuximab Sensitive: B - Late Trials FOLFIRI + cetuximab Sensitive : B	FOLFIRI + cetuximab Sensitive: B - Late Trials FOLFIRI + cetuximab Sensitive : B
BRAF mutation	Acute Myelogenous Leukemia	BRAF mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
BRAF mutation	Melanoma	BRAF mutation	Melanoma	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B
BRAF mutation	Melanoma	BRAF mutation	Melanoma	ipilimumab Sensitive: B - Late Trials ipilimumab Sensitive : B	ipilimumab Sensitive: B - Late Trials ipilimumab Sensitive : B
BRAF mutation	Melanoma	BRAF mutation	Melanoma	KIN-2787 Sensitive: B - Late Trials KIN-2787 Sensitive : B	KIN-2787 Sensitive: B - Late Trials KIN-2787 Sensitive : B
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	panitumumab Sensitive: C2 – Inclusion Criteria panitumumab Sensitive : C2	panitumumab Sensitive: C2 – Inclusion Criteria panitumumab Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	encorafenib + binimetinib Sensitive: C2 – Inclusion Criteria encorafenib + binimetinib Sensitive : C2	encorafenib + binimetinib Sensitive: C2 – Inclusion Criteria encorafenib + binimetinib Sensitive : C2
BRAF mutation	Thyroid Gland Carcinoma	BRAF mutation	Thyroid Gland Carcinoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
BRAF mutation	Thyroid Gland Anaplastic Carcinoma	BRAF mutation	Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C2 – Inclusion Criteria atezolizumab + cobimetinib Sensitive : C2	atezolizumab + cobimetinib Sensitive: C2 – Inclusion Criteria atezolizumab + cobimetinib Sensitive : C2
BRAF mutation	Colon Cancer	BRAF mutation	Colon Cancer	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
BRAF mutation	Pancreatic Cancer	BRAF mutation	Pancreatic Cancer	vemurafenib Sensitive: C2 – Inclusion Criteria vemurafenib Sensitive : C2	vemurafenib Sensitive: C2 – Inclusion Criteria vemurafenib Sensitive : C2
BRAF mutation	Thyroid Gland Papillary Carcinoma	BRAF mutation	Thyroid Gland Papillary Carcinoma	vemurafenib Sensitive: C2 – Inclusion Criteria vemurafenib Sensitive : C2	vemurafenib Sensitive: C2 – Inclusion Criteria vemurafenib Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2
BRAF mutation	Rectal Cancer	BRAF mutation	Rectal Cancer	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	nivolumab + bevacizumab Sensitive: C2 – Inclusion Criteria nivolumab + bevacizumab Sensitive : C2	nivolumab + bevacizumab Sensitive: C2 – Inclusion Criteria nivolumab + bevacizumab Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	vemurafenib + cobimetinib Sensitive: C2 – Inclusion Criteria vemurafenib + cobimetinib Sensitive : C2	vemurafenib + cobimetinib Sensitive: C2 – Inclusion Criteria vemurafenib + cobimetinib Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	cobimetinib Sensitive: C2 – Inclusion Criteria cobimetinib Sensitive : C2	cobimetinib Sensitive: C2 – Inclusion Criteria cobimetinib Sensitive : C2
BRAF mutation	Thyroid Gland Anaplastic Carcinoma	BRAF mutation	Thyroid Gland Anaplastic Carcinoma	vemurafenib Sensitive: C2 – Inclusion Criteria vemurafenib Sensitive : C2	vemurafenib Sensitive: C2 – Inclusion Criteria vemurafenib Sensitive : C2
BRAF mutation	Non Small Cell Lung Cancer	BRAF mutation	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
BRAF mutation	Non Small Cell Lung Cancer	BRAF mutation	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
BRAF mutation	Melanoma	BRAF mutation	Melanoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3

BRAF mutation

Associations